Disc Medicine, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on the stock and has a $118.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight the promising outlook for Disc Medicine. Firstly, the company’s drug candidate, bitopertin, has been awarded the Commissioner’s National Priority Voucher (CNPV) by the FDA, which significantly shortens the review period for its approval. This voucher suggests a high likelihood of approval, as the FDA tends to select applications with clear data for expedited review. Additionally, bitopertin has received Orphan Drug Designation and Rare Pediatric Disease Designation, further supporting its potential for approval.
Moreover, Disc Medicine is actively preparing for the commercial launch of bitopertin, with a fully staffed commercial team ready to engage with the EPP patient community. The company has also ensured that the commercial supply chain is well-managed. Tsao’s valuation of Disc Medicine includes a price target of $118, based on a risk-adjusted revenue estimate and the probability of success for various pipeline assets. Despite some risks, such as regulatory approval and financial challenges, the overall prospects for Disc Medicine appear strong, justifying the Buy rating.
In another report released on October 3, Morgan Stanley also maintained a Buy rating on the stock with a $90.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year.